Who is sponsoring NCT04120090?

NCT04120090 is sponsored by Beijing Friendship Hospital.

What drugs are being tested in NCT04120090?

Interventions in NCT04120090: low dose ruxolitinib, high dose ruxolitinib.

What condition does NCT04120090 study?

NCT04120090 studies Hemophagocytic Lymphohistiocytosis.

Is NCT04120090 still recruiting?

NCT04120090 is currently status unknown. Last updated 29 October 2019.

Last reviewed 2019-10-29 · How we verify

NCT04120090

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis

Status unknown Phase 3 Last updated 29 October 2019

What this trial tests

Phase 3 trial testing low dose ruxolitinib in Hemophagocytic Lymphohistiocytosis in 80 participants. Status unknown.

Timeline

1 July 2019

Primary endpoint
1 July 2020

1 July 2020

Quick facts

Lead sponsor	Beijing Friendship Hospital
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 July 2019
Primary completion	1 July 2020
Estimated completion	1 July 2020
Sites	1 location across China

Drugs / interventions tested

low dose ruxolitinib — full drug profile →
high dose ruxolitinib — full drug profile →

Conditions studied

Hemophagocytic Lymphohistiocytosis — all drugs for Hemophagocytic Lymphohistiocytosis →

Sponsor

Beijing Friendship Hospital

Who can join

Adults 1 to 75, any sex, with Hemophagocytic Lymphohistiocytosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to investigate the efficacy and safety of different doses of ruxolitinib as a salvage therapy for refractory/relapsed hemophagocytic lymphohistiocytosis(HLH).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Liu B, Li M, Zhou Z, Guan X, et al · · 2020 · cited 507× · PMID 32291137 · DOI 10.1016/j.jaut.2020.102452
Pediatric hemophagocytic lymphohistiocytosis.
Canna SW, Marsh RA. · · 2020 · cited 338× · PMID 32107531 · DOI 10.1182/blood.2019000936
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
Luo Y, Alexander M, Gadina M, O'Shea JJ, et al · · 2021 · cited 92× · PMID 34625141 · DOI 10.1016/j.jaci.2021.08.004
The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature.
Wang A, Singh K, Ibrahim W, King B, et al · · 2020 · cited 64× · PMID 32226347
Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.
Eskandarian Boroujeni M, Sekrecka A, Antonczyk A, Hassani S, et al · · 2022 · cited 58× · PMID 35663932 · DOI 10.3389/fimmu.2022.888897
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.
Wu Y, Sun X, Kang K, Yang Y, et al · · 2024 · cited 47× · PMID 39511607 · DOI 10.1186/s13045-024-01621-x
Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies.
Yildiz H, Bailly S, Van Den Neste E, Yombi JC. · · 2021 · cited 28× · PMID 33888986 · DOI 10.2147/tcrm.s195538
Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review.
Yarmohammadi A, Yarmohammadi M, Fakhri S, Khan H. · · 2021 · cited 27× · PMID 33038418 · DOI 10.1016/j.ejphar.2020.173620

Verify or expand the search:

Other Beijing Friendship Hospital trials

Trials by the same sponsor.

NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04120090 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
Last refreshed: 29 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04120090.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing